120 related articles for article (PubMed ID: 16018938)
61. Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?
Denham JW; Steigler A; Wilcox C; Lamb DS; Joseph D; Atkinson C; Tai KH; Spry NA; Gleeson PS; D'Este C
Cancer; 2009 Oct; 115(19):4477-87. PubMed ID: 19691097
[TBL] [Abstract][Full Text] [Related]
62. Prostate-specific antigen velocity in untreated, localized prostate cancer.
Venkitaraman R; Norman A; Woode-Amissah R; Dearnaley D; Horwich A; Huddart R; Parker C
BJU Int; 2008 Jan; 101(2):161-4. PubMed ID: 17850368
[TBL] [Abstract][Full Text] [Related]
63. Should we replace the Gleason score with the amount of high-grade prostate cancer?
Vis AN; Roemeling S; Kranse R; Schröder FH; van der Kwast TH
Eur Urol; 2007 Apr; 51(4):931-9. PubMed ID: 16935413
[TBL] [Abstract][Full Text] [Related]
64. Gleason Pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials.
Nanda A; Chen MH; Renshaw AA; D'Amico AV
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1419-23. PubMed ID: 19131185
[TBL] [Abstract][Full Text] [Related]
65. Avoidance of anticipated regret: the ordering of prostate-specific antigen tests.
Sorum PC; Mullet E; Shim J; Bonnin-Scaon S; Chasseigne G; Cogneau J
Med Decis Making; 2004; 24(2):149-59. PubMed ID: 15090101
[TBL] [Abstract][Full Text] [Related]
66. Using splines to detect changes in PSA doubling times.
Guess B; Jennrich R; Johnson H; Redheffer R; Scholz M
Prostate; 2003 Feb; 54(2):88-94. PubMed ID: 12497581
[TBL] [Abstract][Full Text] [Related]
67. The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer.
Hall WH; Jani AB; Ryu JK; Narayan S; Vijayakumar S
Prostate Cancer Prostatic Dis; 2005; 8(1):22-30. PubMed ID: 15700051
[TBL] [Abstract][Full Text] [Related]
68. Use of quality indicators to evaluate the care of patients with localized prostate carcinoma.
Miller DC; Litwin MS; Sanda MG; Montie JE; Dunn RL; Resh J; Sandler H; Wei JT
Cancer; 2003 Mar; 97(6):1428-35. PubMed ID: 12627506
[TBL] [Abstract][Full Text] [Related]
69. Does 'peer coaching' increase GP capacity to promote informed decision making about PSA screening? A cluster randomised trial.
Gattellari M; Donnelly N; Taylor N; Meerkin M; Hirst G; Ward JE
Fam Pract; 2005 Jun; 22(3):253-65. PubMed ID: 15824055
[TBL] [Abstract][Full Text] [Related]
70. Preliminary treatment considerations among men with newly diagnosed prostate cancer.
Zeliadt SB; Moinpour CM; Blough DK; Penson DF; Hall IJ; Smith JL; Ekwueme DU; Thompson IM; Keane TE; Ramsey SD
Am J Manag Care; 2010 May; 16(5):e121-30. PubMed ID: 20455638
[TBL] [Abstract][Full Text] [Related]
71. Factors associated with pattern of care before surgery for breast cancer in Quebec between 1992 and 1997.
Shen N; Mayo NE; Scott SC; Hanley JA; Goldberg MS; Abrahamowicz M; Tamblyn R
Med Care; 2003 Dec; 41(12):1353-66. PubMed ID: 14668668
[TBL] [Abstract][Full Text] [Related]
72. [PSA doubling times of prostate carcinoma managed with watchful observation alone].
Dunst J
Strahlenther Onkol; 2001 Dec; 177(12):684-5. PubMed ID: 11789411
[No Abstract] [Full Text] [Related]
73. Feasibility and limitations of comorbidity measurement in patients undergoing radical prostatectomy.
Froehner M; Koch R; Litz RJ; Oehlschlaeger S; Hakenberg OW; Wirth MP
Eur Urol; 2005 Feb; 47(2):190-5; discussion 195. PubMed ID: 15661413
[TBL] [Abstract][Full Text] [Related]
74. Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer.
Kim SP; Gross CP; Nguyen PL; Smaldone MC; Thompson RH; Shah ND; Kutikov A; Han LC; Karnes RJ; Ziegenfuss JY; Tilburt JC
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):163-9. PubMed ID: 24566445
[TBL] [Abstract][Full Text] [Related]
75. Validation of increasing prostate specific antigen as a predictor of prostate cancer death after treatment of localized prostate cancer with surgery or radiation.
Albertsen PC; Hanley JA; Penson DF; Fine J
J Urol; 2004 Jun; 171(6 Pt 1):2221-5. PubMed ID: 15126789
[TBL] [Abstract][Full Text] [Related]
76. Prostate cancer: out of the closet.
Lesesne JB
J Med Assoc Ga; 1998 Jan; 87(1):23-6. PubMed ID: 9666644
[No Abstract] [Full Text] [Related]
77. Treatment choice for benign prostatic hyperplasia: a matter of urologist preference?
Stoevelaar HJ; Van de Beek C; Casparie AF; McDonnell J; Nijs HG
J Urol; 1999 Jan; 161(1):133-8. PubMed ID: 10037385
[TBL] [Abstract][Full Text] [Related]
78. Intermediate- to high-risk prostate cancer patient treated with radiation therapy.
Crawford ED; Barqawi A
Oncology (Williston Park); 2004 Aug; 18(9):1105-10. PubMed ID: 15471196
[No Abstract] [Full Text] [Related]
79. The trend of managing prostate cancer in Taiwan.
Wong WY; Chen SC; Chueh SC; Chen J
Int J Urol; 2004 Jul; 11(7):510-4. PubMed ID: 15242360
[TBL] [Abstract][Full Text] [Related]
80. Changing physician PSA ordering patterns through education.
Skelton NK; Skelton WP
Arch Intern Med; 1994 Apr; 154(7):819-20. PubMed ID: 7511886
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
